US FDA-approved disease-modifying treatments for multiple sclerosis: review of adverse effect profiles.
Several disease-modifying agents (DMAs) are approved for the treatment of multiple sclerosis, including three interferon (IFN)-beta products, glatiramer acetate and mitoxantrone. This article reviews the adverse event profiles of these DMAs based on the pivotal phase III trials, and provides practical guidelines for managing adverse effects. In general, the most common adverse events associated with IFN beta therapy are flu-like symptoms, including fever, chills and myalgias, and headache. The flu-like symptoms typically resolve within 24 hours and may be mitigated by over-the-counter anti-inflammatory agents. Adverse events related to glatiramer acetate therapy include injection-site reactions and a systemic reaction consisting of flushing, chest tightness, palpitation, anxiety or dyspnoea. The systemic reaction is transient (30 seconds to 30 minutes) and self-limited. Mitoxantrone may cause nausea, vomiting, alopecia, amenorrhoea and myelosuppression; isolated cases of acute leukaemia and dose-related cardiotoxicity have been reported in the literature. Longer-term tolerability data on mitoxantrone as a treatment for multiple sclerosis are needed. It is important for physicians to counsel patients on DMA-related adverse effects, most of which are transient and of mild-to-moderate severity. Various strategies that can be employed to prevent or manage these adverse effects and lessen their impact on the patient are discussed.
Galetta
Steven L
SL
Department of Neurology, University of Pennsylvania Hospital, Philadelphia, Pennsylvania 19104, USA. galetta@mail.med.upenn.edu
Markowitz
Clyde
C
D002986:Clinical Trials as Topic; D017277:Drug Approval; D006801:Humans; D009103:Multiple Sclerosis / Q000188:drug therapy*; D014481:United States; D014486:United States Food and Drug Administration
Lancet. 2002 Dec 21-28;360(9350):2018-25
12504397
Can J Neurol Sci. 2004 Feb;31(1):58-63
15038472
Mult Scler. 2002 Oct;8(5):441-5
12356214
Ann Neurol. 1996 Mar;39(3):285-94
8602746
Lancet. 1998 Nov 7;352(9139):1498-504
9820297
Neurology. 1999 Nov 10;53(8):1622-7
10563602
Mult Scler. 2003 Mar;9(2):213-4
12708818
Drugs Aging. 1997 Jun;10(6):473-85
9205852
Neurology. 2001 May 22;56(10):1416
11376205
Arch Dermatol. 1999 Oct;135(10):1277-8
10522686
N Engl J Med. 2000 Sep 28;343(13):898-904
11006365
Neurology. 2002 Sep 24;59(6):954-5
12297591
Neurology. 2002 Nov 26;59(10):1496-506
12451188
Arch Neurol. 1997 May;54(5):531-3
9152109
Mult Scler. 1996 Jul;1(6):329-32
9345411
Neurology. 1993 Apr;43(4):655-61
8469318
Neurology. 2001 Jun 26;56(12):1628-36
11425926
J Behav Med. 1997 Oct;20(5):433-45
9415854
Neurology. 2002 Nov 26;59(10 ):1507-17
12451189
Neurology. 2002 Sep 10;59(5):679-87
12221157
Neurology. 2001 Jun 12;56(11):1496-504
11402106
Drug Saf. 2003;26(11):815-27
12908850
Neurology. 1998 Jun;50(6):1910-2
9633761
Drugs. 1991 Mar;41(3):400-49
1711446
Lancet. 1998 Nov 7;352(9139):1491-7
9820296
J Neurol. 2003 Feb;250(2):241-2
12622093
Leukemia. 1998 Mar;12(3):441-2
9529141
Cutis. 2001 Oct;68(4):287-8
11710450
Neurology. 1996 Jan;46(1):12-8
8559358
J Neurol Neurosurg Psychiatry. 2003 Dec;74(12):1689-92
14638892
Neurology. 1998 Feb;50(2):570-1
9484407
Arch Intern Med. 2002 Oct 28;162(19):2161-9
12390057
J Neurol. 1997 Mar;244(3):153-9
9050955
J Neurol. 2000 Mar;247(3):220-1
10787120
Clin Ther. 1997 Sep-Oct;19(5):883-93
9385477
Neurology. 1995 Jul;45(7):1268-76
7617181
Lancet. 2002 Apr 27;359(9316):1453-60
11988242
Drug Saf. 2000 Feb;22(2):149-59
10672896
Neurology. 2002 Apr 23;58(8 Suppl 4):S10-22
11971122
Neurology. 1995 Jul;45(7):1277-85
7617182
Mult Scler. 2003 Feb;9(1):59-62
12617270
Am J Gastroenterol. 2002 Mar;97(3):767-8
11922585
Neurologist. 2002 Jul;8(4):227-36
12803682
J Neurol. 1996 Apr;243(4 Suppl 1):S23-6
8965117
Leukemia. 2003 May;17(5):985-6
12750718
Neurol Sci. 2003 Dec;24(5):361-4
14716534
Neurology. 2004 Feb 24;62(4):628-31
14981183